<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942708</url>
  </required_header>
  <id_info>
    <org_study_id>STU 052009-009</org_study_id>
    <secondary_id>UL1RR024982</secondary_id>
    <nct_id>NCT00942708</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension</brief_title>
  <official_title>Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and efficacy of open-label fluoxetine for
      three months among patients with pulmonary arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary arterial hypertension (PAH) is a life-threatening disorder of uncertain
      cause that leads to progressive right heart failure and death. Average survival has improved
      from about 2.8 years in the early 1990s to approximately 5-7 years with current treatments,
      but most patients will still die of their disease. Two classes of oral medications are
      approved for use in PAH: endothelin-1 antagonists, and phosphodiesterase-5 inhibitors. Both
      improve walk distance and symptoms in PAH, but most patients still have continued dyspnea,
      fatigue and significant elevations in pulmonary pressures. Those who remain severely impaired
      are generally started on a continuous intravenous prostacyclin. For those who are less ill
      but still symptomatic, few options are available.

      Primary endpoint: the primary endpoint will be change in pulmonary vascular resistance (PVR)
      measured by right heart catheterization after three months of therapy.

      Secondary endpoints

        -  Six minute walk distance

        -  QIDS-SR depression scale

      Safety and tolerability endpoints will include a tabulation of adverse events to include but
      not limited to:

        -  Death

        -  Hospitalization

        -  Symptomatic hypotension

        -  Gastrointestinal side effects

        -  Depression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulmonary Vascular Resistance (PVR) at Three Months</measure>
    <time_frame>Change in PVR at 3 mos (Baseline - 3 months)</time_frame>
    <description>PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Between Baseline and Three Month in the QIDS-SR Depression Scale</measure>
    <time_frame>Baseline - 3 months (median change)</time_frame>
    <description>The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) depression scale is a questionnaire completed by the patient. Lower scores are better. Scoring can be interpreted as 7 or less: normal, 8-12: mild depression, 13-16 moderate depression, 17-20 moderate to severe depression and &gt;20 severe depression. Results here show the median change between baseline and 3 months, making a positive change in score indicative of improvement. Total minimum score is 0 and the maximum is 27.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Six Minute Walk Distance at 3 Months</measure>
    <time_frame>3 months</time_frame>
    <description>Six minute walk distance will be measured at baseline and after 3 months of fluoxetine. Change in walk distance (mean and SD) will be reported by taking subtracting baseline values from result at 3 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Total dose How to take:
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID</description>
    <arm_group_label>Fluoxetine</arm_group_label>
    <other_name>Total dose How to take:</other_name>
    <other_name>Week 1-2 20 mg daily</other_name>
    <other_name>Week 3-4 40 mg daily</other_name>
    <other_name>Week 5-6 40 mg BID</other_name>
    <other_name>Week 7-12 40mg BID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent prior to any study-mandated procedure

          2. PAH of the following subtypes: idiopathic PAH WHO functional class II-III

          3. Catheterization within one week showing mPAP &gt;=25, wedge or LV end diastolic pressure
             â‰¤15, and PVR &gt; 4 wood units, and baseline fick cardiac output results available

          4. Age 16-75

          5. Able to complete a six minute walk distance

          6. Women of childbearing potential*: negative serum pre-treatment pregnancy test +
             consistently and correctly uses a reliable method of contraception** Oral approved PAH
             therapy for &gt;3 months with no change in dose for &gt; 1 month

        Exclusion Criteria:

          1. PAH with connective tissue disease, congenital heart disease, portal hypertension,
             glycogen storage disease, Gaucher's disease, hereditary hemorrhagic telangiectasia,
             hemoglobinopathy, myeloproliferative disorders.

          2. Moderate to severe obstructive or restrictive lung disease: forced expiratory volume
             in 1 second/forced vital capacity (FEV1/FVC) &lt; 70% and FEV1 &lt; 60% of predicted value
             after bronchodilator administration. -or- total lung capacity (TLC) &lt; 60% of
             predicted.

          3. Systemic systolic blood pressure &lt;100 mmHg Breastfeeding

          4. Significant liver, renal or other medical disease preventing completion of the study
             procedures or with life expectancy &lt;12 months, or any other acute or chronic physical
             impairment (other than dyspnea), limiting the ability to comply with study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly M Chin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 19, 2009</study_first_submitted>
  <study_first_submitted_qc>July 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <results_first_submitted>February 3, 2019</results_first_submitted>
  <results_first_submitted_qc>April 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2019</results_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluoxetine</title>
          <description>In this single arm study, participants begin fluoxetine at 20 mg daily. If tolerated, the dose is increased every 2 weeks as follows:
Starting dose: 20 mg daily (week 1-2) Next dose: 40 mg daily (week 3-4) Next dose: 40 mg twice daily (week 5-12)
If unable to tolerate uptitration, participants may remain at a lower dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluoxetine</title>
          <description>Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
Fluoxetine: :
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-12 40 mg BID</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pulmonary Vascular Resistance (PVR) at Three Months</title>
        <description>PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value.</description>
        <time_frame>Change in PVR at 3 mos (Baseline - 3 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>Fluoxetine will be started at 20 mg and increased every 2 weeks as tolerated to 80 mg daily.
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-12 40 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulmonary Vascular Resistance (PVR) at Three Months</title>
          <description>PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value.</description>
          <units>Wood units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Single group evaluation of change in PVR between 12 weeks and baseline (T-test for one group, 2-sided, p&lt;0.05 considered significant)</non_inferiority_desc>
            <p_value>0.09</p_value>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Between Baseline and Three Month in the QIDS-SR Depression Scale</title>
        <description>The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) depression scale is a questionnaire completed by the patient. Lower scores are better. Scoring can be interpreted as 7 or less: normal, 8-12: mild depression, 13-16 moderate depression, 17-20 moderate to severe depression and &gt;20 severe depression. Results here show the median change between baseline and 3 months, making a positive change in score indicative of improvement. Total minimum score is 0 and the maximum is 27.</description>
        <time_frame>Baseline - 3 months (median change)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change Between Baseline and Three Month in the QIDS-SR Depression Scale</title>
          <description>The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) depression scale is a questionnaire completed by the patient. Lower scores are better. Scoring can be interpreted as 7 or less: normal, 8-12: mild depression, 13-16 moderate depression, 17-20 moderate to severe depression and &gt;20 severe depression. Results here show the median change between baseline and 3 months, making a positive change in score indicative of improvement. Total minimum score is 0 and the maximum is 27.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Six Minute Walk Distance at 3 Months</title>
        <description>Six minute walk distance will be measured at baseline and after 3 months of fluoxetine. Change in walk distance (mean and SD) will be reported by taking subtracting baseline values from result at 3 months.</description>
        <time_frame>3 months</time_frame>
        <population>All patients completing the 12 week study were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>Fluoxetine will be started at 20 mg and increased every 2 weeks as tolerated to 80 mg daily.
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-12 40 mg twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Six Minute Walk Distance at 3 Months</title>
          <description>Six minute walk distance will be measured at baseline and after 3 months of fluoxetine. Change in walk distance (mean and SD) will be reported by taking subtracting baseline values from result at 3 months.</description>
          <population>All patients completing the 12 week study were analyzed</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluoxetine</title>
          <description>Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
Fluoxetine:
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-12 40mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain or tightness</sub_title>
                <description>Developed chest pain during a line malfunction event (see other AE). Required hospital admission</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Line malfunction</sub_title>
                <description>Patient was receiving a continuous iv medication (not a study medication) and developed a line problem. Required hospital admission and line replacement.</description>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Shaking</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lack of concentration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kelly Chin</name_or_title>
      <organization>UT Southwestern</organization>
      <phone>214-645-5989</phone>
      <email>kelly.chin@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

